Taysha Gene Therapies, Inc. (TSHA)

Over the past six months, Taysha regained full global rights to TSHA-102 after the Option Agreement with Astellas expired. The company presented positive clinical data for TSHA-102, showing a well-tolerated safety profile and a 100% response rate on the primary endpoint. Taysha reported a loss of $0.09 per share in its last quarterly earnings, missing estimates, but surpassed revenue expectations, leading to a stock increase. The company granted stock options to new employees as employment inducements. Analysts have a bullish sentiment with an average 12-month price target of $9.769. TSHA stock has seen significant increases over the last month, six months, and year, but has also experienced volatility.

Information regarding specific demand seasonality for Taysha Gene Therapies' products and services is not publicly detailed. Demand for its product candidates is primarily driven by clinical trial progress, regulatory milestones, and eventual market approval, rather than typical consumer seasonality.

Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company focused on discovering, developing, and commercializing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company's pipeline includes product candidates such as TSHA-102 for Rett syndrome, TSHA-120 for giant axonal neuropathy, and TSHA-121 for CLN7 disease, among others. Taysha also has a strategic partnership with The University of Texas Southwestern Medical Center for research and development efforts.

Taysha Gene Therapies, Inc. is headquartered in Dallas, Texas, United States. While incorporated in 2019, its clinical trials suggest a broader reach in patient enrollment and scientific collaborations.

Taysha Gene Therapies positions itself as a patient-centric company committed to the rare disease community, emphasizing integrity, accountability, and teamwork. The company's focus on advancing its lead clinical program in Rett syndrome and its pipeline of CNS programs contributes to a generally favorable brand perception within its specialized area.

Taysha Gene Therapies, Inc. has significant institutional ownership, with 272 institutional owners and shareholders holding a total of 269,152,062 shares, representing approximately 94.76% of the company. Insiders own about 11.15%. Major institutional owners include Rtw Investments, Lp, Ra Capital Management, L.p., and Avoro Capital Advisors LLC, among others.